SB-649,915

SB-649,915 is a drug that was developed by GlaxoSmithKline for the treatment of depression. It acts as a potent and selective 5-HT1A receptor antagonist, and has been researched for its potential antidepressant effects.

History

SB-649,915 was developed by the pharmaceutical company GlaxoSmithKline. It was designed to act as a potent and selective antagonist for the 5-HT1A receptor, a type of serotonin receptor that is often targeted in the treatment of depression and other mood disorders.

Mechanism of Action

SB-649,915 works by blocking the action of the 5-HT1A receptor. This receptor is one of several that are activated by serotonin, a neurotransmitter that is involved in the regulation of mood, appetite, and sleep. By blocking the action of this receptor, SB-649,915 may help to increase the availability of serotonin in the brain, which could potentially improve symptoms of depression.

Clinical Trials

While SB-649,915 has been studied in clinical trials, it has not yet been approved for use in the treatment of depression. The results of these trials have not been publicly disclosed, so it is not currently known how effective this drug may be in treating depression or what side effects it may cause.

See Also

• 5-HT1A receptor
• Serotonin receptor
• GlaxoSmithKline

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  SB-649,915